top of page
HOME
ABOUT US
SOCIAL IMPACT
STRATEGY
GENE THERAPY
CELL THERAPY
RNA-BASED THERAPY
TARGETED THERAPIES
MICROBIOME
TEAM
PORTFOLIO
CURRENT PORTFOLIO
PAST PORTFOLIO
NEWSROOM
CONTACT
More
Use tab to navigate through the menu items.
NEWSROOM
4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A
Dec 6, 2022
SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa
Dec 1, 2022
4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics
Nov 16, 2022
Araris Biotech Closes $24 Million Financing Round
Oct 4, 2022
4BIO Capital Portfolio Company Carisma Therapeutics and Sesen Bio Announce Merger Agreement
Sep 21, 2022
SparingVision Raises €75 Million Series B
Sep 14, 2022
2
3
4
5
6
ARCHIVE
March 2025
(1)
1 post
January 2025
(1)
1 post
November 2024
(3)
3 posts
October 2024
(3)
3 posts
May 2024
(1)
1 post
April 2024
(1)
1 post
March 2024
(1)
1 post
January 2024
(1)
1 post
November 2023
(2)
2 posts
August 2023
(1)
1 post
June 2023
(1)
1 post
May 2023
(2)
2 posts
December 2022
(2)
2 posts
November 2022
(1)
1 post
October 2022
(1)
1 post
September 2022
(2)
2 posts
June 2022
(2)
2 posts
April 2022
(1)
1 post
March 2022
(1)
1 post
February 2022
(1)
1 post
SEARCH BY TAGS
portfolio
(27)
27 posts
4BIO Ventures II
(20)
20 posts
investment
(10)
10 posts
appointment
(8)
8 posts
collaboration
(8)
8 posts
4BIO Ventures III
(6)
6 posts
Orchard Therapeutics
(6)
6 posts
SparingVision
(6)
6 posts
acquisition
(5)
5 posts
advisory board
(4)
4 posts
approval
(4)
4 posts
Araris
(4)
4 posts
publication
(4)
4 posts
Ascend
(3)
3 posts
CodeBio
(3)
3 posts
Ray Therapeutics
(3)
3 posts
Spark Therapeutics
(3)
3 posts
Takeda
(3)
3 posts
ViaNautis
(3)
3 posts
AAV
(2)
2 posts
ADC Therapeutics
(2)
2 posts
Carisma
(2)
2 posts
IPO
(2)
2 posts
Kyowa Kirin
(2)
2 posts
Redpin Therapeutics
(2)
2 posts
review
(2)
2 posts
TiGenix
(2)
2 posts
4BATLE
(1)
1 post
AI
(1)
1 post
AMED
(1)
1 post
awards
(1)
1 post
BLA
(1)
1 post
Chugai
(1)
1 post
clinical trials
(1)
1 post
DBJ
(1)
1 post
EBV
(1)
1 post
EGLS
(1)
1 post
Eli Lilly
(1)
1 post
Entact
(1)
1 post
ETF
(1)
1 post
exit
(1)
1 post
Fierce 15
(1)
1 post
grant
(1)
1 post
Harbor Capital
(1)
1 post
Hornet Therapeutics
(1)
1 post
IND
(1)
1 post
Insig AI
(1)
1 post
Intellia
(1)
1 post
Luca Science
(1)
1 post
March Bio
(1)
1 post
merger
(1)
1 post
Moderna
(1)
1 post
pricing
(1)
1 post
results
(1)
1 post
Taiho
(1)
1 post
Trogenix
(1)
1 post
venture
(1)
1 post
FOLLOW US
bottom of page
